Immunovia

Immunovia CEO Jeff Borcherding, one of the Company’s largest shareholders, intends to exercise all warrants he purchased in the rights issue. In addition, all board members who currently hold TO 3 warrants—Martin Møller, Hans Johansson and Peter Høngaard Andersen—have communicated their intention to fully exercise the TO 3 warrants they hold. In total, holders of 825,834 TO 3 warrants have communicated their intention to fully exercise their TO3 warrants during the exercise period that is currently on-going.

“Immunovia has a very bright future. The funds from the warrants will finance the commercial launch of the next generation test in Q3 and additional clinical studies to secure payer reimbursement. The board and I are excited to exercise our TO 3 warrants and support these investments.” said Jeff Borcherding, Immunovia’s CEO.

One (1) warrant series TO 3 entitles the holder to subscribe for one (1) new share in the Company at a subscription price of SEK 0.24 per share. The exercise period runs until April 15, 2025. Last day of trading in warrants of series TO 3 is April 11, 2025, and the outcome of the exercise of warrants will be published via a press release on or around April 17, 2025.